Cavalier Investments’s Enanta Pharmaceuticals ENTA Stock Holding History

Cavalier Investments’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-12,000	Closed	-$850K	–	132
2018 Q4	$850K	Buy	12,000 +4,400	+58%	+$337K	0.27%	76
2018 Q3	$649K	Hold	7,600	–	–	0.19%	100
2018 Q2	$880K	Buy	7,600 +1,700	+29%	+$170K	0.3%	72
2018 Q1	$477K	Buy	+5,900	New	+$454K	0.17%	99

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Cavalier Investments's ENTA Position: Q1 2019 in Review

Cavalier Investments sold out of Enanta Pharmaceuticals (ENTA) in Q1 2019, closing a stake of 12,000 shares — an estimated $850K sold.

Cavalier Investments first reported a position in ENTA in Q1 2018 and held it in 4 quarters. The position peaked at $880K in Q2 2018. 195 funds tracked by Wall St. Rank hold ENTA as of Q1 2019.

Cavalier Investments reported no remaining Enanta Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Cavalier Investments sold 12,000 Enanta Pharmaceuticals shares in Q1 2019, an estimated $850K.
Cavalier Investments first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 4 quarters.
Cavalier Investments's Enanta Pharmaceuticals position peaked at $880K in Q2 2018.
195 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2019.

Based on Cavalier Investments's 13F filing for Q1 2019, filed 3 May 2019.